TSX runs higher on rate cut expectations
Alexandria Forbes, President and CEO of MeiraGTx Holdings PLC (NASDAQ:MGTX), sold 47,500 ordinary shares of the company on July 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $7.97, for a total transaction value of $378,575. The sale comes as MGTX shares have shown remarkable strength, posting a 100% return over the past year and trading near their 52-week high of $8.75.
The prices for the shares sold ranged from $7.73 to $8.15. The sale was executed under a Rule 10b5-1 trading plan adopted by Forbes on August 21, 2024. According to InvestingPro analysis, MGTX currently appears overvalued, with analysts setting price targets between $13 and $50. The company’s financial health score is rated as "FAIR," with 13 additional ProTips available for subscribers. Following the transaction, Forbes directly owns 1,361,483 ordinary shares of MeiraGTx Holdings PLC.
In other recent news, MeiraGTx Holdings plc has received regulatory clearances in the United Kingdom (TADAWUL:4280) for its proposed transactions with Hologen Limited. The transactions, initially agreed upon in March 2025, are expected to be finalized by July 2025. Additionally, MeiraGTx announced that its gene therapy product AAV-GAD has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration. This designation is based on positive outcomes from three clinical studies for the treatment of Parkinson’s disease, highlighting the therapy’s potential benefits for patients whose symptoms are inadequately managed by current medications. The RMAT status will expedite the development and review process, offering benefits similar to Fast Track and Breakthrough Therapy designations. Dr. Alexandria Forbes, President and CEO of MeiraGTx, noted the significant findings from their partnership with Hologen, which used AI technology to reveal potential disease-modifying changes in patients’ brain circuitry. This development underscores MeiraGTx’s commitment to advancing genetic medicine through its broad pipeline and in-house manufacturing capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.